Ezetimibe (SCH-58235) - Moligand™, 10mM in DMSO , Niemann-Pick C1-like protein 1 inhibitor, CAS No.163222-33-1, Niemann-Pick C1-like protein 1 inhibitor

CAS: 163222-33-1 Cat. No.: E408174 Summenformel: C24H21F2NO3 Molekulargewicht: 409.43 EG-Nummer: 682-606-0
Zu bestellen verfügbar
GRADE & PURITY Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 10mM in DMSO
Synonyms
(3R,​4S)​-1-​(4-​fluorophenyl)​-​3-​[(3S)​-​3-​(4-​fluorophenyl)​-​3-​hydroxypropyl]​-​4-​(4-​hydroxyphenyl)​-​2-​azetidinone
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
Size
Deutschland (EU)
USA*
Price
Qty
1ml
E408174-1ml
1 Auf Lager

95,36€

138,75€
Speichern 43,39 € (31.27%)
Enter a quantity for the sizes you want to add.
🧪

Why this grade

Moligand™, 10mM in DMSO Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 7 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Übersicht

Information

Ezetimibe (SCH-58235) Ezetimibe (SCH-58235) is a potent, selective, cholesterol absorption inhibitor, used to lower cholesterol.
In vitro

Ezetimibe produces a significant reduction in total cholesterol, LDL cholesterol, and triglycerides as well as a small but significant increase in HDL cholesterol. Ezetimibe reduces cholesterol transport by 31% in Caco-2 cells, but not retinol transport. Ezetimibe results in a significant decrease in mRNA expression for the surface receptors SR-BI, Niemann-Pick type C1 Like 1 protein (NPC1L1), and ATP-binding cassette transporter, subfamily A (ABCA1) and for the nuclear receptors retinoid acid receptor (RAR)gamma, sterol-regulatory element binding proteins (SREBP)-1 and -2, and liver X receptor (LXR)beta as assessed by real-time PCR analysis in Caco-2 cells.

In vivo

Ezetimibe reduces plasma cholesterol levels from 964 to 374 mg/dL, from 726 to 231 mg/dL, and from 516 to 178 mg/dL in the western, low-fat, and cholesterol-free diet mice, respectively. Ezetimibe reduces aortic atherosclerotic lesion surface area from 20.2% to 4.1% in the western diet group and from 24.1% to 7.0% in the low-fat cholesterol diet mice. Ezetimibe reduces carotid artery atherosclerotic lesion cross-sectional area by 97% in the western and low-fat cholesterol groups and by 91% in the cholesterol-free mice. Ezetimibe inhibits cholesterol absorption, reduces plasma cholesterol, increases high density lipoprotein levels, and inhibits the progression of atherosclerosis under western, low-fat, and cholesterol-free dietary conditions in apoE-/- mice. Ezetimibe potently inhibits the transport of cholesterol across the intestinal wall, thereby reducing plasma cholesterol in preclinical animal models of hypercholesterolemia. Ezetimibe eliminates exocrine pancreatic function from the intestine while maintaining bile flow, is established in the rat. Ezetimibe reduces plasma cholesterol and hepatic cholesterol accumulation in cholesterol-fed hamsters with an ED(50) of 0.04 mg /kg.
Cell Data

cell lines:

Concentrations:

Incubation Time:

Powder Purity:≥99%

Specifications

Synonyme
(3R,​4S)​-1-​(4-​fluorophenyl)​-​3-​[(3S)​-​3-​(4-​fluorophenyl)​-​3-​hydroxypropyl]​-​4-​(4-​hydroxyphenyl)​-​2-​azetidinone
Spezifikationen & Reinheit
Moligand™, 10mM in DMSO
Biochemische und physiologische Mechanismen
Ezetimibe (SCH-58235) is a potent, selective, cholesterol absorption inhibitor, used to lower cholesterol.
Storage
Store at -80°C
Verschickt in
Dry ice packs + Cold packs
Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.
Note
Moligand™
Aktionsart
ANTAGONIST, INHIBITOR
Mechanismus der Wirkung
Niemann-Pick C1-like protein 1 inhibitor
Produkteigenschaften
ALogP4
Namen und Kennungen
Isomere SMILES C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O
Alternative CAS-Nummer 163222-33-1
MeSH-Eintrag (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone);58235, SCH;ezetimib;ezetimibe;Ezetrol;SCH 58235;SCH-58235;SCH58235;Zetia
Molekulargewicht 409.43
Reaxy-Rn 11745669
Reaxys-RN_link_address https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=11745669&ln=

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Zugehörige Ziele (menschlich)
NPC1L1 Tclin NPC1-like intracellular cholesterol transporter 1 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

1 results found

Lot NumberCertificate TypeDatumArtikel
L2214620Certificate of AnalysisJul 22, 2026 E408174
Chemische und physikalische Eigenschaften
LöslichkeitSolubility (25°C) In vitro Ethanol: mg/mL    
Schmelzpunkt (°C)327.2 - 330.8 °C
FAQs und Artikel
Citations of This Product
Referenzen
1. Chao Meng, Lingye Zhou, Lin Huang, Qi Gu, Xinyue Du, Cheng Wang, Fanglan Liu, Chunhua Xia.  (2023)  Chlorogenic acid regulates the expression of NPC1L1 and HMGCR through PXR and SREBP2 signaling pathways and their interactions with HSP90 to maintain cholesterol homeostasis.  PHYTOMEDICINE,      [PMID:38103317] [10.1016/j.phymed.2023.155271]
2. Qiuyao Du, Yunfeng Zhang, Jifen Wang, Bingjie Liu.  (2020)  Simultaneous determination and quantitation of hypolipidemic drugs in fingerprints by UPLC-Q-TRAP/MS.  JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES,      [PMID:33991956] [10.1016/j.jchromb.2020.122496]
3. Yao Pan, Ze-Yuan Deng, Xuan Chen, Bing Zhang, Yawei Fan, Hongyan Li.  (2020)  Synergistic antioxidant effects of phenolic acids and carotenes on H2O2-induced H9c2 cells: Role of cell membrane transporters.  FOOD CHEMISTRY,      [PMID:33059273] [10.1016/j.foodchem.2020.128000]
4. Ziyao Liu, Xiaohui Zhan, Minggang Yang, Qi Yang, Xianghui Xu, Fang Lan, Yao Wu, Zhongwei Gu.  (2016)  A magnetic-dependent protein corona of tailor-made superparamagnetic iron oxides alters their biological behaviors.  Nanoscale,  (14): (7544-7555).  [PMID:26949199] [10.1039/C5NR08447D]
5. Juan Zhou, Yi-Qiao Xu, Sheng-Ya Guo, Chun-Qi Li.  (2014)  Rapid analysis of hypolipidemic drugs in a live zebrafish assay.  JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS,      [PMID:25497901] [10.1016/j.vascn.2014.12.002]
6. Wenyue Yu, Yangyu Zhou, Ya Liu, Huan Guo, Lihui Huang, Jinrong Bai, Yue Xiao, Yanping Wu, Kai Zhong, Yina Huang, Hong Gao.  (2025)  Gut Microbial Catabolism of Prebiotic Theabrownin Yields Bioactive Metabolites for Gut Health and Lipid Homeostasis.  JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY,      [PMID:41085220] [10.1021/acs.jafc.5c10211]
7. Xiaoxue He, Tian Liu, Mingjia Sun, Linsheng Wu, Yinghou Wang, Jingdong Xiao, Jin Sun, Qikun Jiang.  (2026)  Ginsenoside-Engineered Lipid Nanoparticles in Microbeads Enable Oral siRNA Delivery and Targeted Therapy for Ulcerative Colitis.  ADVANCED FUNCTIONAL MATERIALS,      [PMID:] [10.1002/adfm.202525241]
Lösungsrechner
Bewertungen

Kundenbewertungen

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.